Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
PHASE2CompletedINTERVENTIONAL
Enrollment
80
Participants
Timeline
Start Date
December 2, 2015
Primary Completion Date
May 28, 2019
Study Completion Date
October 23, 2020
Conditions
Mediastinal Large B-cell LymphomaRichter Syndrome
Interventions
BIOLOGICAL
Pembrolizumab
IV infusion
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT02576990 - Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) | Biotech Hunter | Biotech Hunter